231 related articles for article (PubMed ID: 18343800)
21. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
Fillekes Q; Natukunda E; Balungi J; Kendall L; Bwakura-Dangarembizi M; Keishanyu R; Ferrier A; Lutakome J; Gibb DM; Burger DM; Walker AS;
J Acquir Immune Defic Syndr; 2011 Dec; 58(4):392-8. PubMed ID: 21926634
[TBL] [Abstract][Full Text] [Related]
22. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
[TBL] [Abstract][Full Text] [Related]
23. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
24. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.
van Luin M; Gras L; Richter C; van der Ende ME; Prins JM; de Wolf F; Burger DM; Wit FW
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):240-5. PubMed ID: 19593159
[TBL] [Abstract][Full Text] [Related]
25. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
[TBL] [Abstract][Full Text] [Related]
26. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Gallien S; Journot V; Rozenbaum W; Yéni P; Morlat P; Poizot-Martin I; Reynes J; Reliquet V; Leclercq P; Simon F; Chêne G; Molina JM;
J Antimicrob Chemother; 2011 Jan; 66(1):184-91. PubMed ID: 21036772
[TBL] [Abstract][Full Text] [Related]
27. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B
Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906
[TBL] [Abstract][Full Text] [Related]
28. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
Cabrera Figueroa S; Fernández de Gatta M; Hernández García L; Domínguez-Gil Hurlé A; Bustos Bernal C; Sepúlveda Correa R; García Sánchez MJ
Ther Drug Monit; 2010 Oct; 32(5):579-85. PubMed ID: 20720517
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of subtherapeutic plasma concentrations of efavirenz in children.
Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):133-6. PubMed ID: 17417100
[TBL] [Abstract][Full Text] [Related]
31. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
[TBL] [Abstract][Full Text] [Related]
33. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR
J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483
[TBL] [Abstract][Full Text] [Related]
34. Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
Sungi SS; Ngaimisi E; Ulenga N; Sasi P; Mugusi S
BMC Pharmacol Toxicol; 2018 Oct; 19(1):66. PubMed ID: 30352627
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.
Carbonara S; Regazzi M; Ciracì E; Villani P; Stano F; Cusato M; Heichen M; Monno L
Ann Pharmacother; 2009 May; 43(5):978-84. PubMed ID: 19383934
[TBL] [Abstract][Full Text] [Related]
37. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
[TBL] [Abstract][Full Text] [Related]
38. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
[TBL] [Abstract][Full Text] [Related]
39. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
